Skip to main content

Table 1 Baseline patient characteristics and optimized background

From: Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients

Characteristics

Valuesa

Age, years

45 (40–51)

Male gender, n (%)

102 (85 %)

Number of previous regimens

6 (4–7)

Years of experienced treatment

13 (9–17)

Baseline HIV-1 plasma viral load, log10 copies/mL

4.35 (3.55–4.66)

Baseline HIV-1 RNA >100,000 copies/mL, n (%)

24 (20 %)

Baseline CD4+ cell counts (cells/μL)

245 (129–400)

Baseline CD4+ cells count <200 cells/μL, n (%)

45 (37.5)

Number of mutations to DRV

1 (0–2)

Number of mutations to DRV ≥2

47 (39 %)

Number of PI RAMs, non-DRV RAMs

4 (3–6)

GSSb for DRV

0.75 (0.5–1.0)

GSSb for OBR

1.5 (1.2–2.0)

TDF in regimen, n (%)

77 (64.2 %)

MVC in regimen, n (%)

13 (10.8 %)

ENF in regimen, n (%)

13 (10.8 %)

ETV in regimen, n (%)

33 (27.5 %)

RAL in regimen, n (%)

106 (88.3 %)

Stanford score for TDF

35 (20–55)

Stanford score for ETV

10 (0–30)

Stanford score for DRV

12.5 (0–20)

Glucose (mg/dL)

85 (79–91)

Creatinine (mg/dL)

0.86 (0.70–1.0)

ALT (IU/dL)

30 (19–48)

Total cholesterol (mg/dL)

167 (136–195)

Triglycerides (mg/dL)

186 (135–260)

  1. ALT alanine transaminase, DRV darunavir, ENF enfuvirtide, ETV etravirine, GSS genotypic susceptibility score, MVC maraviroc, PI protease inhibitor, RAL raltegravir, RAM resistance-associated mutation, TDF tenofovir
  2. aValues are medians with (interquartile ranges), unless indicated otherwise
  3. bGenotypic score according to the Stanford HIVdb